167 related articles for article (PubMed ID: 36647217)
1. Radiologic Subtypes and Treatment Outcome of Unclassifiable Type
Lee JH; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
J Korean Med Sci; 2023 Jan; 38(3):e16. PubMed ID: 36647217
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
[TBL] [Abstract][Full Text] [Related]
3. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
Chae G; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0226121. PubMed ID: 35950842
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes of the interstitial lung disease subtype of unclassifiable type Mycobacterium avium complex pulmonary disease.
Park YE; Lee JH; Chong YP; Lee HJ; Kim HC; Song JW; Shim TS; Jo KW
J Infect Chemother; 2022 Aug; 28(8):1112-1118. PubMed ID: 35400550
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
Ramirez J; Mason C; Ali J; Lopez FA
J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study.
Zaheen A; Hirama T; Mehrabi M; Brode SK; Marras TK
Respir Med; 2020 Jun; 167():105967. PubMed ID: 32421543
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0052822. PubMed ID: 36326247
[TBL] [Abstract][Full Text] [Related]
8. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
Ye JJ; Wu TS; Chiang PC; Lee MH
J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of
Kim MA; Park YE; Chong YP; Shim TS; Jo KW
J Korean Med Sci; 2022 Oct; 37(40):e292. PubMed ID: 36254530
[TBL] [Abstract][Full Text] [Related]
10. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
[TBL] [Abstract][Full Text] [Related]
11. Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type
Jung J; Chong YP; Lee HJ; Shim TS; Jo K-W
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0100323. PubMed ID: 37843254
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.
Lee BY; Kim S; Hong Y; Lee SD; Kim WS; Kim DS; Shim TS; Jo KW
Antimicrob Agents Chemother; 2015; 59(6):2972-7. PubMed ID: 25753634
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
Lee JH; Park YE; Chong YP; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0152221. PubMed ID: 34930036
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.
Zo S; Kim H; Kwon OJ; Jhun BW
Microbiol Spectr; 2022 Aug; 10(4):e0108822. PubMed ID: 35950873
[TBL] [Abstract][Full Text] [Related]
15. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
[TBL] [Abstract][Full Text] [Related]
16. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex-pulmonary disease in patients unsuitable for standard treatment regimen.
Bao S; Chen S; Zheng J; Ma J; Yang J; Huang H; Duan H
Int J Antimicrob Agents; 2024 Feb; 63(2):107061. PubMed ID: 38103753
[TBL] [Abstract][Full Text] [Related]
18. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease.
Kim OH; Kwon BS; Han M; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Clin Infect Dis; 2019 May; 68(11):1870-1876. PubMed ID: 30239615
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.
Ito M; Koga Y; Hachisu Y; Murata K; Sunaga N; Maeno T; Hisada T
Respir Investig; 2022 Sep; 60(5):613-624. PubMed ID: 35781424
[TBL] [Abstract][Full Text] [Related]
20. Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression.
Pan SW; Shu CC; Feng JY; Wang JY; Chan YJ; Yu CJ; Su WJ
Clin Infect Dis; 2017 Sep; 65(6):927-934. PubMed ID: 28541556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
